# Fulcrum Therapeutics, Inc.: financial statements, quarterly

FULC · Nasdaq · CIK 1680581 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/fulc.md) · [Financials](/companies/fulc/financials.md) · [Filings](/companies/fulc/filings.md) · [Insiders](/companies/fulc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/fulc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.8](/filings/0000950170-24-125931.md) | [0.9 d](/filings/0000950170-25-026068.md) | [0.0](/filings/0000950170-24-058193.md) | [80.0](/filings/0000950170-25-099407.md) | [0.0](/filings/0001193125-25-254633.md) | [0.0 d](/filings/0001193125-26-065197.md) | not reported | [0.0](/filings/0000950170-25-099407.md) | [0.0](/filings/0001193125-25-254633.md) | [0.0 d](/filings/0001193125-26-065197.md) | not reported | not reported |
| Research and development | $m | [18.2](/filings/0000950170-24-125931.md) | [19.0 d](/filings/0000950170-25-026068.md) | [19.8](/filings/0000950170-25-061442.md) | [17.3](/filings/0000950170-25-099407.md) | [14.6](/filings/0001193125-25-254633.md) | [11.7 d](/filings/0001193125-26-065197.md) | [13.4](/filings/0001193125-26-178814.md) | [13.0](/filings/0001193125-26-326098.md) | [14.3](/filings/0001193125-25-254633.md) | [15.4 d](/filings/0001193125-26-065197.md) | [14.1](/filings/0001193125-26-178814.md) | [12.4](/filings/0001193125-26-326098.md) |
| Operating income | $m | [(27.4)](/filings/0000950170-24-125931.md) | [(28.0) d](/filings/0000950170-25-026068.md) | [(29.8)](/filings/0000950170-25-061442.md) | [52.5](/filings/0000950170-25-099407.md) | [(25.1)](/filings/0001193125-25-254633.md) | [(19.4) d](/filings/0001193125-26-065197.md) | [(20.4)](/filings/0001193125-26-178814.md) | [(19.8)](/filings/0001193125-26-326098.md) | [(21.9)](/filings/0001193125-25-254633.md) | [(22.7) d](/filings/0001193125-26-065197.md) | [(22.2)](/filings/0001193125-26-178814.md) | [(29.3)](/filings/0001193125-26-326098.md) |
| Net income | $m | [(24.0)](/filings/0000950170-24-125931.md) | [(24.8) d](/filings/0000950170-25-026068.md) | [(26.9)](/filings/0001193125-25-254633.md) | [55.4](/filings/0001193125-25-254633.md) | [(21.7)](/filings/0001193125-25-254633.md) | [(16.6) d](/filings/0001193125-26-065197.md) | [(17.7)](/filings/0001193125-26-326098.md) | [(17.3)](/filings/0001193125-26-326098.md) | [(19.6)](/filings/0001193125-25-254633.md) | [(20.3) d](/filings/0001193125-26-065197.md) | [(18.9)](/filings/0001193125-26-326098.md) | [(26.2)](/filings/0001193125-26-326098.md) |
| Diluted EPS | $ per share | [(0.39)](/filings/0000950170-24-125931.md) | not reported | [(0.43)](/filings/0000950170-25-061442.md) | [0.87](/filings/0000950170-25-099407.md) | [(0.35)](/filings/0001193125-25-254633.md) | not reported | [(0.28)](/filings/0001193125-26-178814.md) | [(0.28)](/filings/0001193125-26-326098.md) | [(0.31)](/filings/0001193125-25-254633.md) | not reported | [(0.25)](/filings/0001193125-26-178814.md) | [(0.34)](/filings/0001193125-26-326098.md) |
| Basic EPS | $ per share | [(0.39)](/filings/0000950170-24-125931.md) | not reported | [(0.43)](/filings/0000950170-25-061442.md) | [0.89](/filings/0000950170-25-099407.md) | [(0.35)](/filings/0001193125-25-254633.md) | not reported | [(0.28)](/filings/0001193125-26-178814.md) | [(0.28)](/filings/0001193125-26-326098.md) | [(0.31)](/filings/0001193125-25-254633.md) | not reported | [(0.25)](/filings/0001193125-26-178814.md) | [(0.34)](/filings/0001193125-26-326098.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [30.1](/filings/0000950170-24-125931.md) | [25.6](/filings/0000950170-25-026068.md) | [39.9](/filings/0000950170-25-061442.md) | [86.7](/filings/0000950170-25-099407.md) | [72.6](/filings/0001193125-25-254633.md) | [58.2](/filings/0001193125-26-065197.md) | [42.2](/filings/0001193125-26-178814.md) | [42.6](/filings/0001193125-26-326098.md) | [47.1](/filings/0001193125-25-254633.md) | [198](/filings/0001193125-26-326098.md) | [50.3](/filings/0001193125-26-178814.md) | [48.5](/filings/0001193125-26-326098.md) |
| Current assets | $m | [262](/filings/0000950170-23-059755.md) | [242](/filings/0000950170-25-026068.md) | [218](/filings/0000950170-24-058193.md) | [280](/filings/0000950170-24-088238.md) | [267](/filings/0000950170-24-125931.md) | [250](/filings/0001193125-26-065197.md) | [233](/filings/0000950170-25-061442.md) | [219](/filings/0000950170-25-099407.md) | [206](/filings/0001193125-25-254633.md) | [357](/filings/0001193125-26-326098.md) | [339](/filings/0001193125-26-178814.md) | [323](/filings/0001193125-26-326098.md) |
| Total assets | $m | [279](/filings/0000950170-23-059755.md) | [258](/filings/0000950170-25-026068.md) | [233](/filings/0000950170-24-058193.md) | [294](/filings/0000950170-24-088238.md) | [279](/filings/0000950170-24-125931.md) | [261](/filings/0001193125-26-065197.md) | [243](/filings/0000950170-25-061442.md) | [229](/filings/0000950170-25-099407.md) | [215](/filings/0001193125-25-254633.md) | [366](/filings/0001193125-26-326098.md) | [347](/filings/0001193125-26-178814.md) | [324](/filings/0001193125-26-326098.md) |
| Current liabilities | $m | [14.1](/filings/0000950170-23-059755.md) | [13.7](/filings/0000950170-25-026068.md) | [10.7](/filings/0000950170-24-058193.md) | [12.7](/filings/0000950170-24-088238.md) | [14.5](/filings/0000950170-24-125931.md) | [11.0](/filings/0001193125-26-065197.md) | [8.1](/filings/0000950170-25-061442.md) | [9.0](/filings/0000950170-25-099407.md) | [11.6](/filings/0001193125-25-254633.md) | [13.0](/filings/0001193125-26-326098.md) | [9.9](/filings/0001193125-26-178814.md) | [10.3](/filings/0001193125-26-326098.md) |
| Total liabilities | $m | [23.4](/filings/0000950170-23-059755.md) | [22.5](/filings/0000950170-25-026068.md) | [19.0](/filings/0000950170-24-058193.md) | [20.5](/filings/0000950170-24-088238.md) | [21.7](/filings/0000950170-24-125931.md) | [17.7](/filings/0001193125-26-065197.md) | [14.2](/filings/0000950170-25-061442.md) | [14.5](/filings/0000950170-25-099407.md) | [16.5](/filings/0001193125-25-254633.md) | [17.3](/filings/0001193125-26-326098.md) | [13.5](/filings/0001193125-26-178814.md) | [13.3](/filings/0001193125-26-326098.md) |
| Shareholders' equity | $m | [255](/filings/0000950170-24-125931.md) | [235](/filings/0001193125-26-065197.md) | [214](/filings/0001193125-25-254633.md) | [274](/filings/0001193125-25-254633.md) | [257](/filings/0001193125-25-254633.md) | [243](/filings/0001193125-26-326098.md) | [228](/filings/0001193125-26-326098.md) | [214](/filings/0001193125-26-326098.md) | [198](/filings/0001193125-25-254633.md) | [349](/filings/0001193125-26-326098.md) | [333](/filings/0001193125-26-326098.md) | [311](/filings/0001193125-26-326098.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(22.9) d](/filings/0000950170-24-125931.md) | [(23.2) d](/filings/0000950170-25-026068.md) | [(25.3)](/filings/0000950170-25-061442.md) | [58.9 d](/filings/0000950170-25-099407.md) | [(19.1) d](/filings/0001193125-25-254633.md) | [(16.8) d](/filings/0001193125-26-065197.md) | [(15.3)](/filings/0001193125-26-178814.md) | [(13.8) d](/filings/0001193125-26-326098.md) | [(14.2) d](/filings/0001193125-25-254633.md) | [(16.8) d](/filings/0001193125-26-065197.md) | [(18.8)](/filings/0001193125-26-178814.md) | [(16.0) d](/filings/0001193125-26-326098.md) |
| Capital expenditure | $m | [0.1 d](/filings/0000950170-24-125931.md) | [0.1 d](/filings/0000950170-25-026068.md) | [0.0](/filings/0000950170-25-061442.md) | [0.0 d](/filings/0000950170-25-099407.md) | [0.0 d](/filings/0001193125-25-254633.md) | [0.2 d](/filings/0001193125-26-065197.md) | [0.0](/filings/0001193125-26-178814.md) | [0.1 d](/filings/0001193125-26-326098.md) | [0.1 d](/filings/0001193125-25-254633.md) | [0.2 d](/filings/0001193125-26-065197.md) | [0.0](/filings/0001193125-26-178814.md) | [0.1 d](/filings/0001193125-26-326098.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q1 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [0.0](/filings/0000950170-23-059755.md) | [0.1](/filings/0000950170-24-058193.md) | [61.8](/filings/0000950170-24-088238.md) | [61.8](/filings/0000950170-24-125931.md) | [62.0](/filings/0000950170-25-061442.md) | [63.6](/filings/0000950170-25-099407.md) | [62.4](/filings/0001193125-25-254633.md) | [62.5](/filings/0001193125-26-178814.md) | [62.5](/filings/0001193125-26-326098.md) | [62.6](/filings/0001193125-25-254633.md) | [76.2](/filings/0001193125-26-178814.md) | [76.3](/filings/0001193125-26-326098.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 76,297,257 at 2026-07-23, from the cover of the [10-Q filed 2026-07-30](/filings/0001193125-26-326098.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.